Status:
WITHDRAWN
Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum
Lead Sponsor:
Wake Forest University Health Sciences
Collaborating Sponsors:
Novartis
Conditions:
Pyoderma Gangrenosum
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The purpose of this research study is to find out what effects (good and bad) secukinumab has on the subject and their pyoderma gangrenosum. Secukinumab is a type of medicine called human monoclonal ...
Detailed Description
This is a prospective, single center, Phase IIa study of secukinumab in the treatment of subjects diagnosed with PG. Subjects will be evaluated at Screening, Baseline (week 0), Week 1, Week 2, Week 3,...
Eligibility Criteria
Inclusion
- 1\. Must give written informed consent. 2. Has a diagnosis of pyoderma gangrenosum, as determined by the investigator based on the following diagnostic criteria4:
- a. Diagnosis requires both major criteria and at least two minor criteria i. Major criteria
- Rapid progression of a painful, necrolytic cutaneous ulcer with an irregular, violaceous, and undermined border
- Other causes of cutaneous ulceration have been excluded ii. Minor criteria
- 1\. History suggestive of pathergy or clinical finding of cribriform scarring 2. Systemic diseases associated with PG 3. Histopathologic findings (sterile dermal neutrophilia, ± mixed inflammation, ± lymphocytic vasculitis) 4. Treatment response (rapid response to systemic steroid treatment)
- 3\. PG global assessment of moderate to severe, with at least one ulcer measuring at least 3 cm in diameter.
- 4\. 18 years of age or greater. 5. Must require systemic therapy for their pyoderma gangrenosum, as determined by the investigator prior to Baseline. Currently prescribed low-dose corticosteroids (≤ 10 mg/day), and other medications within one week prior to investigational drug administration, may be continued with no change in dose or frequency during the study.
Exclusion
- Female subjects who are not postmenopausal for at least 1 year, surgically sterile, or willing to practice effective contraception during the study. Nursing mothers, pregnant women and women planning to become pregnant while on study are to be excluded.
- Current enrollment in any investigational study in which the subject is receiving any type of drug, biologic, or non-drug therapy (participation in registry-type studies is allowed).
- Serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., pneumonia, septicemia) within the 3 months prior to the first dose of investigational drug.
- Treatment with another investigational drug or approved therapy for investigational use within 28 days prior to investigational drug administration.
- Treatment with high dose (\>10 mg/day) systemic steroids (prednisone) within one week prior to investigational drug administration. Treatment with cyclosporine, thalidomide, methotrexate, mycophenolate mofetil, azathioprine, or other systemic immunosuppressant agents within the 14 days prior to investigational drug administration (requirement of a 2-week washout).
- Known HIV+, known viral hepatitis infection, known tuberculosis infection.
- Any subject with a current or history of a malignancy in the last five years (excluding treated basal cell carcinoma).
- Clinically significant abnormal laboratory measures at screening.
- Known Irritable Bowel Disease-associated PG
Key Trial Info
Start Date :
May 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04274166
Start Date
May 1 2021
End Date
April 1 2022
Last Update
May 28 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.